November 2022
Leveraging CRISPR-Cas9 screening platform for discovery of novel tumor intrinsic phagocytosis modulators
November 2022
Whole genome CRISPR-Cas9 screens in a cancer cell line panel co-cultured with antigen-specific cytotoxic CD8 T cells are a powerful engine for immuno-oncology drug target discovery
November 2022
In vivo CRISPR screens identify HDAC1 as an immune sensitizer reversing immune resistance driven by STK11 loss
November 2022
TNG260, a CoREST-selective deacetylase inhibitor, reverses anti-PD1 resistance driven by loss of STK11
October 2022
TNG462 is a potential best-in-class MTA-cooperative PRMT5 inhibitor for the treatment of peripheral MTAP-deleted solid tumors
